This HTML5 document contains 178 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
n12http://dx.doi.org/10.1016/
schemahttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q34046989
rdf:type
wikibase:Item
schema:description
мақолаи илмӣ 2016年论文 2016 nî lūn-bûn artykuł naukowy teaduslik artikkel 2016年論文 naučni članak articol științific vetenskaplig artikel სამეცნიერო სტატია videnskabelig artikel (udgivet 2016) artículu científicu espublizáu en 2016 ২০১৬-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ مقالة علمية 2016年論文 2016年论文 научная статья سائنسی مضمون mokslinis straipsnis artikulong pang-agham 2016 թուականի Յունիսին հրատարակուած գիտական յօդուած 2016年论文 2016年の論文 vedecký článok artigo científico (publicado na 2016) wetenschappelijk artikel article scientifique (publié 2016) bài báo khoa học vědecký článek scienca artikolo wissenschaftlicher Artikel 2016年论文 artigo científico (publicado na 2016) наукова стаття, опублікована в червні 2016 2016年論文 مقالهٔ علمی επιστημονικό άρθρο บทความทางวิทยาศาสตร์ мақолаи илмӣ artigo científico 2016年论文 научна статия vitenskapelig artikkel artikull shkencor 2016 թվականի հունիսին հրատարակված գիտական հոդված 2016年论文 2016年論文 научни чланак vitskapeleg artikkel articolo scientifico tieteellinen artikkeli article científic научни чланак tudományos cikk artículo científico publicado en 2016 2016년 논문 2016年論文 מאמר מדעי bilimsel makale article scientific scientific article ശാസ്ത്രപ്രബന്ധം​
p:P577
wds:Q34046989-B7AC5E40-3A4B-4326-8BB0-D21BB340A7E4
wdt:P577
2016-06-09T00:00:00Z
p:P407
wds:Q34046989-857C4E04-F498-423A-868D-7F56856CE752
wdt:P407
wd:Q1860
p:P2860
wds:Q34046989-AFFBF27B-BAE5-4862-BAD5-784DBD4D510A wds:Q34046989-B79347F1-A8CB-4D95-A59F-2E9B117C23B5 wds:Q34046989-C22A5A59-4EE7-4205-85CA-D4F3C7834BF8 wds:Q34046989-CDB322CB-EF3F-4E61-8D48-DD24040B299E wds:Q34046989-CED28F39-2676-4976-A4EA-B3194C8BEB53 wds:Q34046989-DE5EE936-CC82-4222-8B55-44AC4B92EA47 wds:Q34046989-E6050D0E-4DF1-48CB-A6BF-FE45C82D30FD wds:Q34046989-E615108A-61DC-4464-B4A0-FB4E0BD984AA wds:Q34046989-F07CE80A-384F-44CF-86AA-115D442C3020 wds:Q34046989-F3382DD7-08CA-472A-9F9C-34FE68124F96 wds:Q34046989-1C9A78E2-6F86-4E8C-947C-088037BB243C wds:Q34046989-32C503B3-31EE-4BF5-AD30-40ADA32F71CA wds:Q34046989-493EBF76-4A87-4913-A0FA-66C0312EB0A9 wds:Q34046989-5C515B5A-5B82-4C09-943A-39240AC69918 wds:Q34046989-5DFB8B1B-62E8-474B-B770-347AEC541CED wds:Q34046989-5FB6453D-DD4E-40D6-82C4-8C61031597C1 wds:Q34046989-68E92C60-5FDA-43C2-BA2C-C368E0545A5F wds:Q34046989-9CF578E2-948A-4F63-9559-70B22E311D0E wds:Q34046989-9D308F5A-C854-443D-AE99-D82871F03177 wds:Q34046989-063B0C2B-4BB0-4B14-8B8A-428911754DC6
wdt:P2860
wd:Q33413862 wd:Q34571867 wd:Q74000597 wd:Q38403603 wd:Q36144210 wd:Q38207986 wd:Q57569718 wd:Q52918395 wd:Q29396936 wd:Q37886394 wd:Q28131668 wd:Q36674041 wd:Q35198579 wd:Q26822530 wd:Q80848516 wd:Q33382803 wd:Q40446756 wd:Q38241990 wd:Q39014708 wd:Q31463890
p:P2093
wds:Q34046989-9B382985-5A05-4D90-AEDD-1A755E71E172 wds:Q34046989-982B0BDC-5388-4923-A2E5-15FC05D31C55 wds:Q34046989-83A37451-EC25-47C0-B3DC-179BAF5A0572 wds:Q34046989-3EDDE8A5-5934-44CF-8DD6-52FF51136ADE wds:Q34046989-39D1FA89-5907-49F1-A1DC-F6A57C0E5032 wds:Q34046989-3BAE7F97-4E17-4EC5-9B8C-DD07D555B249 wds:Q34046989-38C4FA34-950E-40DB-A3C4-B2701035F00D wds:Q34046989-5725EECB-C7AA-43C5-B9F3-48B2F4D5C017 wds:Q34046989-CBD29EBA-4FDD-48D1-BD21-18B6077BD33E wds:Q34046989-B7267C8E-D02C-4727-B936-5480D9991F07 wds:Q34046989-AE5A9F6B-CA87-41F1-A02D-EEF17A34BE4D wds:Q34046989-DBFBF255-C702-444E-B8BF-370C68A6A070 wds:Q34046989-0FCAA923-011F-475D-8AF1-B81272A1472F wds:Q34046989-0141ABC7-8F80-45D6-8272-0EAF7FB44687 wds:Q34046989-03B35887-C577-4646-9C94-A284256BE421 wds:Q34046989-7BA0BA0D-7624-4DB5-B852-AC80EBFFF5F9 wds:Q34046989-72A9E8AD-FB8A-492C-9126-24D3A74C1E3A
wdt:P2093
Amy Qin Michael B Livingston Damien M Cronier Ashwin Shahir Douglas Adkins Meera R Hameed Jan Cosaert Robert Ilaria Gregory Pennock Anthony D Elias Gary K Schwartz Mark Agulnik William D Tap Matthew M Cooney Gaurav D Shah Ilaria Conti Brian A Van Tine
rdfs:label
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
skos:prefLabel
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
schema:name
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
p:P50
wds:Q34046989-5D10AFC6-CF14-42AA-9BBC-207EEC63C714 wds:Q34046989-CCA96632-99CB-4113-9E77-538A4D021684
wdt:P50
wd:Q84574401 wd:Q32649618
p:P1476
wds:Q34046989-66B031C4-5131-4AF2-B2C1-9B569CC8E17E
wdt:P1476
Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial
p:P304
wds:Q34046989-59806EEA-D8AC-4D08-899C-AE4C0EDE513E
wdt:P304
488-497
p:P31
wds:Q34046989-75B5BE6A-B864-4E68-8AA0-618CE1927D39
wdt:P31
wd:Q13442814
p:P921
wds:Q34046989-66A76AC6-1492-4DD8-9CE4-BA3377221711 wds:Q34046989-703AB179-8A0E-4BEA-98DB-F1F29F265C27
wdt:P921
wd:Q18936 wd:Q42824440
p:P698
wds:Q34046989-382D180D-154F-4D6F-B747-19E950809B3F
wdtn:P698
n11:27291997
wdt:P698
27291997
p:P1433
wds:Q34046989-730E1AAE-D76B-4346-B663-756572B71E37
wdt:P1433
wd:Q939416
p:P433
wds:Q34046989-9641A4E1-ACB2-4C10-956F-CB0ECB79023A
p:P478
wds:Q34046989-451490AB-DAED-4EA5-8539-37EB862EE173
wdt:P433
10043
wdt:P478
388
p:P356
wds:Q34046989-6C88183B-9900-4752-8D3D-5EDC43BFB8CB
wdtn:P356
n12:S0140-6736(16)30587-6
wdt:P356
10.1016/S0140-6736(16)30587-6
p:P932
wds:Q34046989-98BC55CD-ABC0-404E-AE25-9C7F93CFF35D
wdt:P932
5647653